Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829614) titled 'F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shandong New Time Pharmaceutical Co., LTD

Condition: Systemic Lupus Erythematosus (SLE)

Intervention: Drug: F182112

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: October 30, 2025

Target Sample Size: 64

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT078296...